Neurent Medical secures €62.5m Series C to scale Neuromark for chronic rhinitis
Neurent Medical CEO Brian Shields with the NEUROMARK Device (photo: Neurent Medical)
Galway-based medical device company Neurent Medical has raised €62.5m in an oversubscribed Series C round to accelerate the commercial expansion of its Neuromark system for the treatment of chronic rhinitis. The financing, announced on 11 February 2026, was led by MVM Partners with significant participation from Sofinnova Partners, alongside existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
The funding marks an important milestone for Neurent as it moves from clinical validation to large-scale commercial execution, particularly in the United States, where demand is growing for in-office treatments that address common, chronic conditions.
A widespread condition with limited options
Chronic rhinitis is characterised by persistent nasal symptoms such as congestion and runny nose that last for months or years. While not life-threatening, the condition can significantly affect sleep, concentration and overall quality of life. Standard treatment typically relies on nasal sprays and oral medication, which are not effective for all patients and often require long-term use.
For those who do not respond adequately to medication, options have historically been limited. This gap between drug therapy and invasive surgery is where Neurent Medical positions Neuromark: as a minimally invasive, outpatient procedure intended to address the underlying neural drivers of chronic rhinitis symptoms.
What Neurent Medical does
Founded in Ireland, Neurent Medical develops medical devices for ear, nose and throat (ENT) specialists. Its flagship product, the Neuromark system, is designed to treat chronic rhinitis by applying controlled radiofrequency energy to the posterior nasal nerve, which plays a key role in regulating nasal symptoms.
The procedure is performed in an outpatient setting by ENT physicians. By targeting nerve signalling rather than relying solely on pharmaceutical management, Neuromark aims to provide durable symptom relief without the need for ongoing medication.
Neurent has received US Food and Drug Administration (FDA) 510(k) clearance for the Neuromark system, a prerequisite for commercial use in the US market and a critical step in the company’s growth strategy.
What makes Neuromark distinctive
Posterior nasal nerve therapies are not new, and Neuromark operates in an increasingly competitive segment of ENT medtech. Neurent differentiates its approach through the design and control mechanisms of its radiofrequency system.
According to the company, Neuromark uses low-power, impedance-controlled radiofrequency energy that allows clinicians to deliver treatment with precision and consistency. The latest generation of the system incorporates real-time feedback and usability improvements developed in collaboration with practising ENT specialists.
In a market where adoption depends heavily on workflow integration and reproducibility, these design choices are central to Neurent’s value proposition.
Clinical evidence and regulatory progress
Clinical evidence is a cornerstone of Neurent’s investment case. Peer-reviewed studies have reported statistically significant and clinically meaningful improvements in chronic rhinitis symptoms following treatment with the Neuromark system, with a favourable safety profile.
In addition, randomised controlled trial data indicate that posterior nasal nerve ablation using Neuromark is superior to a sham procedure in reducing symptoms. While longer-term and comparative data remain important, the use of randomised study designs strengthens Neurent’s clinical positioning relative to earlier-generation devices.
Beyond peer-reviewed publications, Neurent continues to publish longer-term outcomes and follow-up data, supporting its claims of durability and safety.
Why investors are backing Neurent
Series C rounds in medtech typically signal a shift from product development to commercial scale. In Neurent’s case, the €62.5m raise is explicitly aimed at expanding US commercial operations, growing the clinical evidence base and advancing the company’s product pipeline.
Brian Shields, chief executive of Neurent Medical, stated that the financing will support broader access to Neuromark for physicians and patients, while enabling the company to build the infrastructure required for sustained growth.
From an investor perspective, several factors stand out:
-
Large addressable market: Chronic rhinitis affects a broad patient population and is routinely managed in ENT practices.
-
Regulatory clearance: FDA 510(k) clearance reduces regulatory risk and enables near-term commercial scaling.
-
Clear clinical workflow: An in-office, minimally invasive procedure aligns with existing ENT practice models.
-
Experienced investor syndicate: The participation of established life sciences investors adds credibility and governance support.
As part of the financing, representatives from MVM Partners and Sofinnova Partners joined Neurent’s board, reinforcing the focus on disciplined growth and international expansion.
How Neurent compares to its peers
Neurent operates alongside other companies targeting chronic rhinitis through nerve-focused interventions.
Aerin Medical, for example, markets RhinAer, a temperature-controlled radiofrequency system for posterior nasal nerve treatment. Stryker, following its acquisition of Arrinex, offers the ClariFix system, which uses cryotherapy rather than radiofrequency energy.
While the underlying clinical goal is similar, the competitive differences lie in system design, clinical data, ease of use and commercial execution. Neurent’s emphasis on impedance-controlled radiofrequency delivery and its growing body of clinical evidence are intended to support differentiation in a crowded field.
A realistic challenge: reimbursement and adoption
Despite growing interest in minimally invasive rhinitis treatments, reimbursement remains an important consideration. Some insurers have taken a cautious stance on posterior nasal nerve therapies, citing the need for additional comparative and long-term data.
This environment places greater importance on Neurent’s stated plans to expand its evidence base. For the company, continued investment in high-quality clinical studies is not only a scientific requirement but a commercial necessity.
What the Series C means for Neurent and the sector
The Series C financing gives Neurent Medical the resources to pursue commercial scale while continuing to strengthen its clinical foundation. For the wider medtech sector, the round reflects sustained investor interest in technologies that address common, non-acute conditions with measurable quality-of-life benefits.
For Neurent, success will depend on execution: converting regulatory clearance and clinical promise into widespread adoption within ENT practices. If achieved, Neuromark could become part of the standard toolkit for managing chronic rhinitis, demonstrating how targeted medical devices can reshape treatment pathways for everyday conditions.
Liked this article? You can support our independent journalism via our page on Buy Me a Coffee. It helps keep MoveTheNeedle.news focused on depth, not clicks.